Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3020% below fair value
$4.21−0.31 (-6.86%)
Close on Nov 20, 2026Market cap $469.46MP/E –Yield –
Gyre Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Gyre Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$15.55M, down 809.3% year over year. For fiscal 2025 it was $11.49M, down 28.9% from the year before. The highest annual figure on record is $16.16M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.49M | -28.9% |
| FY2024 | Dec 31, 2024 | $16.16M | – |
| FY2023 | Dec 31, 2023 | -$67.23M | -830.5% |
| FY2022 | Dec 31, 2022 | $9.20M | – |
| FY2021 | Dec 31, 2021 | -$87.89M | – |
| FY2020 | Dec 31, 2020 | -$57.37M | – |
| FY2019 | Dec 31, 2019 | -$57.28M | – |
| FY2018 | Dec 31, 2018 | -$33.82M | – |
| FY2017 | Dec 31, 2017 | -$21.82M | – |
| FY2016 | Dec 31, 2016 | -$20.42M | – |
| FY2015 | Dec 31, 2015 | -$13.80M | – |
| FY2014 | Dec 31, 2014 | -$7.51M | – |
| FY2013 | Dec 31, 2013 | -$10.12M | – |
| FY2012 | Dec 31, 2012 | -$8.14M | – |
| FY2011 | Dec 31, 2011 | -$9.75M | -174.3% |
| FY2010 | Dec 31, 2010 | $13.12M | – |
| FY2009 | Dec 31, 2009 | -$40.33M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.52M | -201.7% |
| Q2 FY2026 | Jun 30, 2026 | -$14.36M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.36M | -511.6% |
| Q4 FY2025 | Dec 31, 2025 | $9.69M | +1357.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.49M | -64.7% |
| Q2 FY2025 | Jun 30, 2025 | -$2.24M | -170.1% |
| Q1 FY2025 | Mar 31, 2025 | $2.27M | -71.8% |
| Q4 FY2024 | Dec 31, 2024 | $665.00K | – |
| Q3 FY2024 | Sep 30, 2024 | $4.23M | -66.8% |
| Q2 FY2024 | Jun 30, 2024 | $3.19M | -35.8% |
| Q1 FY2024 | Mar 31, 2024 | $8.07M | +21.1% |
| Q4 FY2023 | Dec 31, 2023 | -$91.63M | – |
| Q3 FY2023 | Sep 30, 2023 | $12.76M | – |
| Q2 FY2023 | Jun 30, 2023 | $4.97M | -90.3% |
| Q1 FY2023 | Mar 31, 2023 | $6.66M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.46M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.17M | – |
| Q2 FY2022 | Jun 30, 2022 | $51.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.70M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.31M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.91M | – |
| Q1 FY2021 | Mar 31, 2021 | -$22.44M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.84M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.36M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.07M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.99M | – |
| Q3 FY2019 | Sep 30, 2019 | -$13.20M | – |
| Q2 FY2019 | Jun 30, 2019 | -$14.38M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.71M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.68M | – |
| Q3 FY2018 | Sep 30, 2018 | -$8.35M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.11M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.68M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.88M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.94M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.17M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.22M | – |
See a number that looks wrong?